GAMMA Investing
TRAX icon

GAMMA Investing’s First Tracks Biotherapeutics TRAX Stock Holding History

GAMMA Investing’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.1K Buy
512
+73
+17% +$2.85K ﹤0.01% 3002
2026
Q2 		$8.83K Buy
+439
New +$8.21K ﹤0.01% 3274

Other funds holding TRAX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Arizona State Retirement System
Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return

GAMMA Investing's TRAX Position: Q3 2026 in Review

GAMMA Investing increased its First Tracks Biotherapeutics (TRAX) stake by 17% in Q3 2026, buying an estimated $2.85K and bringing the position to 512 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

GAMMA Investing first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 36 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

  • GAMMA Investing held 512 shares of First Tracks Biotherapeutics worth $18.1K as of Q3 2026.
  • GAMMA Investing bought 73 First Tracks Biotherapeutics shares in Q3 2026, an estimated $2.85K.
  • First Tracks Biotherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3002 holding.
  • GAMMA Investing first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 36 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.